Hardy Diagnostics partners with NEMIS Technologies to bring N-Light, a rapid on-site pathogen detection system, to the U.S. food safety market. Learn more.
Explore how Pictor’s ViraScreen-Core multiplex antibody assay aligns with evolving CDC hepatitis B testing guidance and what it means for clinical diagnostics.
Soin Neuroscience and BIOTRONIK Neuro have announced a research collaboration focused on evaluating novel waveform technology and adaptive spinal cord stimulation programming aimed at enhancing chronic pain treatment outcomes. The partnership integrates proprietary signal tuning algorithms from Soin Neuroscience with the programmable Prospera SCS system developed by BIOTRONIK Neuro, reinforcing a broader industry shift toward
Wasatch BioLabs has announced a co-marketing agreement with Agilent Technologies to expand access to its Direct Targeted Methylation Sequencing (dTMS) platform. The partnership integrates Agilent’s SureSelect and Avida enrichment chemistries with Wasatch BioLabs’ Oxford Nanopore-based native-read workflow, aiming to streamline high-throughput targeted sequencing for research use only (RUO) and translational settings. The announcement marks a
New I-SPY 2 data suggest personalized ctDNA could transform risk stratification in therapy-resistant early breast cancer. Read the full analysis.
May Health’s Anavi System wins CE Mark. Find out what this means for PCOS infertility care, clinical adoption, and regulatory pathways in Europe.
BlueWind Medical secures FDA clearance for an enhanced Revi wearable. Find out why usability may define the next phase of neuromodulation adoption.
Detect-ION, a diagnostics-focused startup based in Tampa, Florida, has announced a collaborative project with the Infectious Diseases Division at Mayo Clinic Florida to develop a non-invasive breath test for detecting Pseudomonas aeruginosa, a leading cause of pneumonia in vulnerable patient populations. Funded through the Mayo Clinic Advanced Innovation Research program, the project aims to address
Bioretec Ltd, the Finland-based medical device developer specializing in fully biodegradable orthopedic implants, has received Breakthrough Device Designation from the U.S. Food and Drug Administration for its RemeOs DrillPin. The designation applies to the use of the biodegradable magnesium-alloy device in pediatric and adult bone fixation procedures, including epimetaphyseal fractures in children over two years
Personalis, Inc. has reported pivotal findings from its NeXT Personal assay in a new Cell publication, highlighting the test’s ability to detect molecular residual disease in stage I to III non-small cell lung cancer. The study, part of the TRACERx initiative and led by Professor Charles Swanton of the Francis Crick Institute and University College